Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL262792 | 1.00 | MAPT (0.35) | MAPTCYP2C9MEN1GAAKMT2A | |
| SCHEMBL262793 | 1.00 | MAPT (0.35) | MAPTCYP2C9MEN1GAAKMT2A | |
| SCHEMBL24075149 | 0.84 | MAPT (0.32) | MAPT | |
| SCHEMBL2393543 | 0.84 | CYP2C9 (0.37) | MAPTCYP2C9 | |
| SCHEMBL2393548 | 0.84 | CYP2C9 (0.37) | MAPTCYP2C9 | |
| SCHEMBL29267513 | 0.84 | CYP2C9 (0.47) | MAPTCYP2C9MEN1GAAKMT2A | |
| SCHEMBL12997966 | 0.82 | CYP2C9 (0.30) | CYP2C9 | |
| SCHEMBL15082131 | 0.82 | GLO1 (0.31) | CYP2C9 | |
| SCHEMBL1902373 | 0.82 | CYP2C9 (0.37) | MAPTCYP2C9MEN1GAAKMT2A | |
| SCHEMBL1902370 | 0.82 | CYP2C9 (0.37) | MAPTCYP2C9MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190106435-A1 | PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES | VIIV HEALTHCARE COMPANY | 2019-04-11 | — | — | US | claimed |
| EP-3260457-A1 | PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES | VIIV Healthcare Company (US) | 2017-12-27 | — | — | EP | claimed |
| EP-2549870-B1 | PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES | VIIV HEALTHCARE CO (US) | 2017-04-19 | — | — | EP | claimed |
| US-20130172551-A1 | Process for Preparing Carbamolypyridone Derivatives and Intermediates | VIIV HEALTHCARE COMPANY | 2013-07-04 | — | — | US | claimed |
| EP-2549870-A1 | PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES | VIIV Healthcare Company (US) | 2013-01-30 | — | — | EP | claimed |
| WO-2011119566-A1 | PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | claimed |
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-07 | — | — | US | disclosed |
| EP-3260457-B1 | PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES | VIIV HEALTHCARE CO (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20200317667-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. | 2020-10-08 | — | — | US | disclosed |
| US-10730888-B2 | Process for the preparation of dolutegravir | MYLAN LABORATORIES LIMITED (IN) | 2020-08-04 | — | — | US | disclosed |
| US-10730874-B2 | Inhibitors of plasma kallikrein and uses thereof | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-10654871-B2 | Process for preparing (3S,11aR)-N-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide | VIIV HEALTHCARE COMPANY (US) | 2020-05-19 | — | — | US | disclosed |
| US-10654870-B2 | Process for preparing substituted pyridinones as intermediates in the preparation of polycyclic carbamoylpyridone derivatives | VIIV HEALTHCARE COMPANY (US) | 2020-05-19 | — | — | US | disclosed |
| US-8383622-B2 | Nitrogen-containing heterocyclic derivative having 11β-hydroxysteroid dehydrogenase type I inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-02-26 | — | — | US | disclosed |
| US-8383622-B2 | Nitrogen-containing heterocyclic derivative having 11β-hydroxysteroid dehydrogenase type I inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-02-26 | — | — | US | disclosed |
| EP-2549870-A1 | PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES | VIIV Healthcare Company (US) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011119566-A1 | PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20100240659-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE HAVING 11SS-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2010-09-23 | — | — | US | disclosed |
| US-20100240659-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE HAVING 11SS-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2010-09-23 | — | — | US | disclosed |
| EP-2163543-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE HAVING 11 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORY ACTIVITY | Shionogi&Co., Ltd. (JP) | 2010-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | MAPT 2953/4885CYP2C9 2250/4885MEN1 686/4885 |
| US-10730888-B2 | Process for the preparation of dolutegravir | SAMHD1, TYMP, DUT | MAPT 3244/4885CYP2C9 17/4885MEN1 4326/4885 |
| US-20100240659-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE HAVING 11SS-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORY ACTIVITY | HSD11B1, HSD3B1, SRD5A1 | MAPT 4629/4885CYP2C9 168/4885MEN1 1843/4885 |
| US-20190106435-A1 | PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES | CPS1, CYP3A4, SDHA | MAPT 1809/4885CYP2C9 16/4885MEN1 2263/4885 |
| US-20130172551-A1 | Process for Preparing Carbamolypyridone Derivatives and Intermediates | CPS1, CYP3A4, DHPS | MAPT 1249/4885CYP2C9 130/4885MEN1 2945/4885 |
| US-10730874-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | MAPT 2953/4885CYP2C9 2250/4885MEN1 686/4885 |
| US-20200317667-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | MAPT 2953/4885CYP2C9 2250/4885MEN1 686/4885 |
| US-10654871-B2 | Process for preparing (3S,11aR)-N-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide | CYP4B1, CYP2F1, CYP4F11 | MAPT 4122/4885CYP2C9 16/4885MEN1 2312/4885 |
| US-10654870-B2 | Process for preparing substituted pyridinones as intermediates in the preparation of polycyclic carbamoylpyridone derivatives | CYP3A4, CYP2B6, CYP4B1 | MAPT 3876/4885CYP2C9 25/4885MEN1 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.